Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

被引:39
|
作者
Zweemer, Annelien J. M. [1 ]
Bunnik, Julia [1 ]
Veenhuizen, Margo [1 ]
Miraglia, Fabiana [1 ]
Lenselink, Eelke B. [1 ]
Vilums, Maris [1 ]
de Vries, Henk [1 ]
Gibert, Arthur [1 ]
Thiele, Stefanie [2 ]
Rosenkilde, Mette M. [2 ]
IJzerman, Adriaan P. [1 ]
Heitman, Laura H. [1 ]
机构
[1] Leiden Univ, Leiden Acad Ctr Drug Res, Dept Med Chem, NL-2333 CC Leiden, Netherlands
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Neurosci & Pharmacol, Copenhagen, Denmark
关键词
PROTEIN-COUPLED RECEPTORS; SMALL-MOLECULE; PHARMACOLOGICAL CHARACTERIZATION; EXTRACELLULAR LOOP; DRUG DISCOVERY; ACTIVATION; IDENTIFICATION; COMPLEX; GPCR; ACETYLCHOLINE;
D O I
10.1124/mol.114.093328
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chemokine receptor CCR2 is a G protein-coupled receptor that is involved in many diseases characterized by chronic inflammation, and therefore a large variety of CCR2 small molecule antagonists has been developed. On the basis of their chemical structures these antagonists can roughly be divided into two groups with most likely two topographically distinct binding sites. The aim of the current study was to identify the binding site of one such group of ligands, exemplified by three allosteric antagonists, CCR2-RA-[R], JNJ-27141491, and SD-24. We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the binding site of the allosteric antagonists and additionally introduced eight single point mutations in CCR2 to further characterize the putative binding pocket. All constructs were studied in radioligand binding and/or functional IP turnover assays, providing evidence for an intracellular binding site for CCR2-RA-[R], JNJ-27141491, and SD-24. For CCR2-RA-[R] the most important residues for binding were found to be the highly conserved tyrosine Y-7.53 and phenylalanine F-8.50 of the NPxxYx((5,6))F motif, as well as V-6.36 at the bottom of TM-VI and K-8.49 in helix-VIII. These findings demonstrate for the first time the presence of an allosteric intracellular binding site for CCR2 antagonists. This contributes to an increased understanding of the interactions of diverse ligands at CCR2 and may allow for a more rational design of future allosteric antagonists.
引用
收藏
页码:358 / 368
页数:11
相关论文
共 50 条
  • [21] Association of chemokine receptor CCR2 polymorphism with myocardial infarction
    Voevoda, M.I.
    Ustinov, S.N.
    Yudin, N.S.
    Dolgikh, M.M.
    Kuznetsova, T.N.
    Maksimov, V.N.
    Kulikov, I.V.
    Gromov, A.A.
    Shabalin, A.V.
    Semaeva, E.V.
    Kobzev, V.F.
    Baum, S.R.
    Gafarov, V.V.
    Malyutina, S.K.
    Romashchenko, A.G.
    Nikitin, Yu.P.
    Doklady Akademii Nauk, 2002, 385 (02) : 279 - 283
  • [22] CCR2: A characteristic chemokine receptor in normal and pathological intestine
    Yuan, Jin
    CYTOKINE, 2023, 169
  • [23] Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2
    Huma, Zil E.
    Sanchez, Julie
    Lim, Herman D.
    Bridgford, Jessica L.
    Huang, Cheng
    Parker, Bradyn J.
    Pazhamalil, Jiann G.
    Porebski, Benjamin T.
    Pfleger, Kevin D. G.
    Lane, J. Robert
    Canals, Meritxell
    Stone, Martin J.
    SCIENCE SIGNALING, 2017, 10 (480)
  • [24] The presence of leukocyte CC-Chemokine receptor 2 (CCR2) in CCR2 knockout mice promotes atherogenesis
    Jian, G
    Van Eck, M
    von der Thüsen, JH
    Maeda, N
    Benson, GM
    Groot, PH
    Van Berkel, TJ
    CIRCULATION, 2003, 108 (17) : 65 - 65
  • [25] Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
    Pasternak, Alexander
    Goble, Stephen D.
    Struthers, Mary
    Vicario, Pasquale P.
    Ayala, Julia M.
    Di Salvo, Jerry
    Kilburn, Ruth
    Wisniewski, Thomas
    DeMartino, Julie A.
    Mills, Sander G.
    Yang, Lihu
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 14 - 18
  • [26] Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist
    Wisniewski, T.
    Bayne, E.
    Flanagan, J.
    Shao, Q.
    Wnek, R.
    Matheravidathu, S.
    Fischer, P.
    Forrest, M. J.
    Peterson, L.
    Song, X.
    Yang, L.
    DeMartino, J. A.
    Struthers, M.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2010, 352 (1-2) : 101 - 110
  • [27] The discovery of MK-0812, a potent and selective CCR2 antagonist
    Yang, Lihu
    Jiao, Richard X.
    Moyes, Chris
    Morriello, Greg
    Butora, Gabor
    Shankaran, K.
    Pasternak, Alexander
    Goble, Steve
    Zhou, Changyou
    MacCoss, Malcolm
    Cumiskey, Anne-Marie
    Peterson, Larry
    Forrest, Mike
    Ayala, Julia M.
    Jin, Hong
    DeMartino, Julie
    Mills, Sander G.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 580 - 580
  • [28] Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis
    Sorensen, TL
    Ransohoff, RM
    Strieter, RM
    Sellebjerg, F
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (07) : 445 - 449
  • [29] Increased intrathecal chemokine receptor CCR2 expression in multiple sclerosis
    Nakajima, Hideto
    Hosokawa, Takafumi
    Ikemoto, Toshiyuki
    Shinoda, Kei-ichi
    Sugino, Masakazu
    Kimura, Fumiharu
    NEUROLOGY, 2008, 70 (11) : A379 - A379
  • [30] PCSK9 regulates the chemokine receptor CCR2 on monocytes
    Grune, Jana
    Meyborg, Heike
    Bezhaeva, Taisiya
    Kappert, Kai
    Hillmeister, Philipp
    Kintscher, Ulrich
    Pieske, Burkert
    Stawowy, Philipp
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 485 (02) : 312 - 318